Pegvisomant (a GH receptor antagonist) has been used in pediatrics to obtain IGF-1 normalization and symptom improvement in patients without a response to surgical treatment, radiotherapy, and SSAs, although the possibility of an increase in tumor size with this medication should be considered (9,13,20). Here, GHR is linked to neoplasm.